Neurokinin B
Based on 1 Customer Validation
Neurokinin B is a tachykinin family peptide that preferentially binds to and activates NK3R over other tachykinin receptors. Neurokinin B preferentially binds to the substance P receptor (SP-N receptor) and mediates acetylcholine release from cholinergic neurons. Neurokinin B regulates the pulsatile release of Kisspeptin and GnRH, stimulates or inhibits the secretion of luteinizing hormone (HY-P2293), regulates reproductive function via metabolic signals, and drives the onset of puberty. Neurokinin B exerts vasoactive effects and induces contraction of isolated guinea pig ileum. Neurokinin B can be used in studies related to hypogonadotropic hypogonadism.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.48%
- CAS No.: 86933-75-7
- Formule: C55H79N13O14S2
- Masse moléculaire:1210.42
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P0197
Neurokinin APeptide Neurotransmitter -
HY-19632
FezolinetantNK3R Antagonist -
HY-P0201
Substance PNeurotransmitter -
HY-P1186
Eledoisin Related PeptideNeurokinin Receptor Activator -
HY-109171
ElinzanetantNK-1/NK-3 Receptor Antagonist -
HY-P0201A
Substance P TFANeurotransmitter -
HY-P0197A
Neurokinin A TFAPeptide Neurotransmitter -
HY-P1183
Locustatachykinin I -
![[Sar9,Met(O2)11]-Substance P](https://file.medchemexpress.com/product_pic/hy-p1012.gif)
HY-P1012
[Sar9,Met(O2)11]-Substance PTachykinin NK1 Receptor Agonist -
![[bAla8]-Neurokinin A(4-10)](https://file.medchemexpress.com/product_pic/hy-p1031.gif)
HY-P1031
[bAla8]-Neurokinin A(4-10) -
HY-P1185
Antagonist GVasopressin Antagonist -
HY-14552
TalnetantNK3 Receptor Antagonist
Activité biologique
Description
IC50 & Target
|
NK3R |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
6 nM
Compound: Neurokinin-B
|
Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells
Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells
|
[PMID: 9871763] |
| CHO | IC50 |
10 nM
Compound: NKB
|
Binding affinity towards human Tachykinin receptor 3 stably expressed in CHO cells using [125I][MePhe7]-NKB as radioligand
Binding affinity towards human Tachykinin receptor 3 stably expressed in CHO cells using [125I][MePhe7]-NKB as radioligand
|
10.1016/0960-894X(95)00313-I |
| CHO | IC50 |
76 nM
Compound: NKB
|
Displacement of ([125I]-His3, MePhe7)-NKB from NK3R (unknown origin) transfected in CHO cells by gamma counting analysis
Displacement of ([125I]-His3, MePhe7)-NKB from NK3R (unknown origin) transfected in CHO cells by gamma counting analysis
|
[PMID: 23473945] |
In Vivo
Neurokinin B (1 nmol; intracerebroventricular injection; single administration) induces a mild and sustained increase in LH concentration in ovary-intact ewes at any stage of the estrous cycle, with a peak reaching 4-6 ng/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Suffolk breed (adult, ovary-intact, random stages of the estrous cycle)[3]
-
Dosage:1 nmol
-
Administration:i.c.v.; single injection
-
Result:Produced a prolonged increase in LH concentrations lasting 2-3 hours in three of five ewes.
Reached peak LH levels of 4-6 ng/mL, similar to late follicular phase concentrations.
Chemical Information
-
CAS No. 86933-75-7
-
Appearance Solid
-
Masse moléculaire 1210.42
-
Formule C55H79N13O14S2
-
Color White to off-white
-
Sequence
Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2
-
Sequence Shortening
DMHDFFVGLM-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
H2O : 20 mg/mL (16.52 mM; ultrasonic and adjust pH to 9 with NH3·H2O)
DMSO : 5 mg/mL (4.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Navarro VM. Interactions between kisspeptins and neurokinin B. Adv Exp Med Biol. 2013;784:325-47. [Content Brief]
[2]. Jayasena CN, et al. Effects of neurokinin B administration on reproductive hormone secretion in healthy men and women. The Journal of clinical endocrinology and metabolism. 2014 Jan;99(1):E19-27. [Content Brief]
[3]. Billings HJ, et al. Neurokinin B acts via the neurokinin-3 receptor in the retrochiasmatic area to stimulate luteinizing hormone secretion in sheep. Endocrinology. 2010 Aug;151(8):3836-46. [Content Brief]
[4]. Laufer R, et al. Neurokinin B is a preferred agonist for a neuronal substance P receptor and its action is antagonized by enkephalin. Proceedings of the National Academy of Sciences of the United States of America. 1985 Nov;82(21):7444-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 0.8262 mL | 4.1308 mL | 8.2616 mL | 20.6540 mL |
| H2O | 5 mM | 0.1652 mL | 0.8262 mL | 1.6523 mL | 4.1308 mL |
| 10 mM | 0.0826 mL | 0.4131 mL | 0.8262 mL | 2.0654 mL | |
| 15 mM | 0.0551 mL | 0.2754 mL | 0.5508 mL | 1.3769 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Neurokinin B Related Classifications
HY-P0242 Related Classifications
Powered by Bioz